Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Charles Schwab Investment Management Inc. grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,127 shares of the company’s stock after purchasing an additional 11,143 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.53% of Entrada Therapeutics worth $3,408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Janus Henderson Group PLC raised its position in shares of Entrada Therapeutics by 10.5% in the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company’s stock valued at $27,358,000 after buying an additional 161,962 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after purchasing an additional 46,512 shares during the last quarter. State Street Corp boosted its stake in Entrada Therapeutics by 5.5% during the third quarter. State Street Corp now owns 469,601 shares of the company’s stock worth $7,504,000 after buying an additional 24,385 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Entrada Therapeutics by 50.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company’s stock valued at $3,225,000 after buying an additional 67,559 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Entrada Therapeutics in the 3rd quarter worth $1,109,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Up 0.6 %

Shares of Entrada Therapeutics stock opened at $9.96 on Friday. The firm has a market cap of $374.45 million, a PE ratio of 6.26 and a beta of -0.14. Entrada Therapeutics, Inc. has a 52 week low of $9.75 and a 52 week high of $21.79. The business’s fifty day simple moving average is $12.05 and its 200-day simple moving average is $15.45.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.69. The company had revenue of $12.25 million for the quarter, compared to analysts’ expectations of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on TRDA. Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, February 25th. Finally, Roth Mkm started coverage on shares of Entrada Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $29.00 price target for the company.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.